TrialAmerican journal of clinical dermatology2024

Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study.

Laurent Mortier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.